Quarterly report pursuant to Section 13 or 15(d)

Sponsored Research and License Agreements (Details)

v3.20.1
Sponsored Research and License Agreements (Details)
1 Months Ended 3 Months Ended
Apr. 30, 2020
USD ($)
Feb. 29, 2020
USD ($)
Jan. 31, 2020
USD ($)
Oct. 31, 2019
USD ($)
agreement
Jan. 31, 2019
USD ($)
Oct. 31, 2018
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Collaborations                
Contingent payments             $ 611,700,000  
Accounts receivable             9,660,000 $ 10,111,000 [1]
Specified Development Events                
Collaborations                
Contingent payments             70,500,000  
Specified Regulatory Events                
Collaborations                
Contingent payments             165,200,000  
Specified Product Launch Events                
Collaborations                
Contingent payments             376,000,000  
Grifols                
Collaborations                
Upfront payment received         $ 30,000,000      
Contingent payments             277,500,000  
Deferred revenue related to upfront payment             2,200,000  
Revenue, cumulative catch-up     $ 25,000,000          
Revenue, remaining performance obligations               $ 5,000,000
Grifols | Research Services                
Collaborations                
Revenue recognized             3,200,000  
Grifols | Licensed Rights                
Collaborations                
Revenue recognized             39,900,000  
Grifols | Commercial Milestones                
Collaborations                
Contingent payments         297,500,000      
Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP                
Collaborations                
Revenue, cumulative catch-up     $ 20,000,000          
Kissei                
Collaborations                
Upfront payment received           $ 33,000,000    
Contingent payments           $ 147,000,000    
Revenue recognized             0  
Revenue, remaining performance obligations             33,000,000  
Aclaris                
Collaborations                
Accounts receivable             1,000,000  
fostamatinib | Grifols                
Collaborations                
Collaborative payment received   $ 20,000,000            
fostamatinib | Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP                
Collaborations                
Contingent payments         $ 20,000,000      
Collaborative payment received   17,500,000            
fostamatinib | Grifols | Creditable advance royalty payment                
Collaborations                
Collaborative payment received   $ 2,500,000            
fostamatinib | Grifols | Maximum                
Collaborations                
Royalty payment as a percentage of net sales         30.00%      
fostamatinib | Kissei                
Collaborations                
Revenue, remaining performance obligations             $ 1,400,000  
fostamatinib | Medison Pharma | Financing arrangement                
Collaborations                
Upfront payment received       $ 5,000,000        
fostamatinib | Medison Pharma | Commercial and license agreements                
Collaborations                
Number of agreements | agreement       2        
Subsequent event | Aclaris                
Collaborations                
Collaborative payment received $ 500,000              
[1] The balance sheet at December 31, 2019 has been derived from the audited financial statements included in Rigel’s Annual Report on Form 10-K for the year ended December 31, 2019.